Roche CEO Schwan puts 3-time Alzheimer's los­er gan­tenerum­ab back in the spot­light as FDA's con­tro­ver­sial Aduhelm OK in­spires block­buster fore­casts

Four years af­ter Roche opt­ed to res­ur­rect its late-stage ef­fort on their Alzheimer’s pro­gram for gan­tenerum­ab fol­low­ing a clear fail­ure, Roche CEO Sev­erin Schwan is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER